Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting
Calithera Biosciences (CALA) announced it will present final results from the CANTATA clinical study at the ASCO 2021 Annual Meeting. This study evaluated the efficacy of telaglenastat combined with cabozantinib versus placebo in patients with advanced renal cell carcinoma (RCC). Topline results revealed no improvement in progression-free survival (PFS). The presentation, led by Dr. Nizar M. Tannir, is set for June 7, 2021, during the Genitourinary Cancer session. Calithera aims to advance targeted therapies for cancer treatment.
- Calithera's CANTATA trial results will be shared at a prominent conference, enhancing visibility.
- The study contributes valuable data to the understanding of treatments for advanced renal cell carcinoma.
- Telaglenastat did not improve progression-free survival compared to placebo, raising concerns about its efficacy.
- Despite ongoing research, the lack of improvement could hinder future investment and development opportunities.
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place virtually June 4-8, 2021.
Earlier this year, Calithera announced topline results from the Phase 2 CANTATA trial, which evaluated the efficacy and safety of the company’s glutaminase inhibitor, telaglenastat, in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic renal cell carcinoma (RCC) who had been treated with one or two prior lines of systemic therapy, including immune checkpoint inhibitor or anti-angiogenic therapy. Results showed that the addition of telaglenastat to cabozantinib did not improve progression-free survival (PFS) in the study population. Additional analyses will be presented.
Following are details of the ASCO 2021 presentation of final CANTATA results:
Title: CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib vs. Pbo + cabozantinib in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC) that progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies
Abstract: 4501
Session Title: Genitourinary Cancer—Kidney and Bladder
Session Time: 6/7/2021 8:00am – 11:00am EDT
Presenter: Nizar M. Tannir, M.D., FACP, Professor, Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. Calithera’s clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release and such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Inc.
CONTACT:
Investors:
Stephanie Wong
ir@Calithera.com
1-650-870-1063
Media:
Hannah Hurdle
hannahhurdle@sambrown.com
1-805-338-4752
FAQ
What are the results of the CANTATA study by Calithera (CALA)?
When will Calithera present the CANTATA study results?
What is the primary focus of Calithera Biosciences?
